Home > Oncology > ASCO 2020 > Genitourinary Cancer > Novel drug for kidney cancers/VHL patients

Novel drug for kidney cancers/VHL patients

Expert
Prof. Eric Jonasch, University of Texas MD Anderson Cancer Center, USA
Conference
ASCO 2020
Trial
Phase 2
Prof. Eric Jonasch (University of Texas MD Anderson Cancer Center, USA) presented the results of a phase 2 trial of MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a in von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC) [1]. The phase 2 trial enrolled 61 patients with VHL and renal masses. Patients received MK-6482 orally once daily until disease progression, unacceptable toxicity, or investigator's or patient's decision to withdraw. Tumour size was evaluated at screening and every 12 weeks thereafter. No patients had progressive disease on treatment and 58 patients (95.1%) remain on treatment. The trial met its primary endpoint and showed an objective response rate in RCC tumours per RECIST by independent review. The confirmed response rate was 27.9%. When also consider...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on